The objective of this study was to define phenotypic changes of antigen-presenting cells (APCs) and T cells in a @entity19 model of antigen-induced airways @entity32 that involves intraperitoneal sensitization with @entity10328 (OVA)/adjuvant followed by antigen aerosolization. We investigated the @entity1412 and T-cell compartments both after sensitization (primary immune response) and after challenge (secondary immune response) at the thoracic lymph nodes (initiation site) and the lung (effector site). Our findings document a major cellular expansion in the lymph nodes after both sensitization and challenge. After sensitization, this expansion was comprised mainly of B cells, a considerable proportion of which expressed B7.2. At this time, T cells were markedly expanded and activated as assessed by @entity26490 expression; further, although @entity19986 and @entity9094 were expressed at this time point, expression of @entity58 , @entity59 , and @entity1312 messenger RNA (mRNA) levels were marginal. However, in vitro stimulation of lymph-node cells with OVA led to cytokine production. In contrast, 24 h after challenge, but not after sensitization, there was a major expansion of dendritic cells and macrophages in the lungs. This expansion was associated with enhanced expression of both @entity24653 . We also observed expansion of activated @entity5168 (+)/ @entity1961 (+) T cells expressing the T helper-2-associated marker T1/ @entity26052 in the lung, most notably 5 d after challenge. Further, @entity58 , @entity59 , and @entity1312 , but not @entity60 mRNA were expressed at high levels 3 h after challenge. This study helps to elucidate the "geography" of immune responses generated in a conventional @entity19 model of @entity32 .

Temporal-spatial analysis of the immune response in a XXXX model of @entity10328 -induced airways @entity32 .

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'allergic airways inflammation'] @entity10328 :: ('282665(Tax:10090)', 'Gene') :: ['ovalbumin'] @entity26052 :: ('17082(Tax:10090)', 'Gene') :: ['ST2'] @entity59 :: ('16191(Tax:10090)', 'Gene') :: ['IL-5'] @entity19986 :: ('14462(Tax:10090)', 'Gene') :: ['GATA-3'] @entity26490 :: ('12515(Tax:10090)', 'Gene') :: ['CD69'] @entity19 :: ('10090', 'Species') :: ['murine'] @entity5168 :: ('12501(Tax:10090)', 'Gene') :: ['CD3'] @entity60 :: ('15978(Tax:10090)', 'Gene') :: ['interferon-gamma'] @entity9094 :: ('20852(Tax:10090)', 'Gene') :: ['signal transducer and activator of transcription-6'] @entity1961 :: ('12504(Tax:10090)', 'Gene') :: ['CD4'] @entity58 :: ('16189(Tax:10090)', 'Gene') :: ['IL-4', 'interleukin (IL)-4'] @entity24653 :: ('12519;12524', 'Gene') :: ['B7.1 and B7.2'] @entity1312 :: ('16163(Tax:10090)', 'Gene') :: ['IL-13'] @entity1412 :: ('MESH:D011125', 'Disease') :: ['APC']
@entity19 :: (10090,Species) :: ['murine']
